×
About 8,640 results

Pfizer and BioNTech Omicron-Targeted Vaccine Delayed: BioNTech CEO
https://www.medscape.com/viewarticle/968657

Feb 17th, 2022 - BERLIN (Reuters) - Delivery of Pfizer and BioNTech SE's vaccine to combat the Omicron COVID-19 variant was delayed by several weeks due to a slower than expected data gathering process, BionTech Chief Executive Ugur Sahin told Germany's Bild on Thursday. Once the vaccine is ready, the company would assess whether it was still needed, Sahin said. ...

Pfizer and BioNTech Omicron-targeted vaccine delayed - BioNTech CEO undefined
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-biontech-omicron-targeted-vaccine-delayed-biontech-ceo-2022-02-16/

BERLIN, Feb 16 (Reuters) - Delivery of Pfizer (PFE.N) and BioNTech SE's vaccine to combat the Omicron COVID-19 variant was delayed by several weeks due to a slower-than expected data gathering process, BionTech Chief Executive Ugur Sahin told Germany's Bild on Thursday. Once the vaccine is ready, the company would assess whether it was still need...

Pfizer and BioNTech Launch Trial of Omicron-Targeted COVID Vaccine
https://www.medscape.com/viewarticle/967191

Jan 26th, 2022 - NEW YORK (Reuters) - Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. Banking on volunteers in the United States, the companies plan to test the immune response generated by ...

Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine undefined
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-biontech-launch-trial-omicron-targeted-covid-vaccine-2022-01-25/

NEW YORK, Jan 25 (Reuters) - Pfizer Inc (PFE.N) and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. Banking on volunteers in the United States, the companies pl...

Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine
https://www.reuters.com/article/health-coronavirus-pfizer-vaccines/pfizer-and-biontech-launch-trial-of-omicron-targeted-covid-vaccine-idUSL1N2U502Y

Jan 25th, 2022 - NEW YORK, Jan 25 (Reuters) - Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune response generated by the Omicron-based vaccine both as a ...

Pfizer CEO Says Omicron-Targeted Vaccine Is Most Likely Outcome
https://www.medscape.com/viewarticle/966363

Jan 11th, 2022 - (Reuters) - Pfizer Inc Chief Executive Albert Bourla on Monday said a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant is likely needed and his company could have one ready to launch by March. Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine version as well as a...

Pfizer And BioNTech Provide Update On Omicron Variant
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant
Pfizer Inc.;

Dec 8th, 2021 - NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vac...

Pfizer-BioNTech COVID-19 Vaccine
https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html
Centers for Disease Control and Prevention (CDC)

General Information: Vaccine: Pfizer-BioNTech COVID-19 Vaccine Diluent: 0.9% sodium chloride (normal saline, preservative-free) Discard vial when there is not enough vaccine to obtain a complete dose. Do NOT combine residual vaccine from multiple vials to obtain a dose.

Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant
https://cdn.pfizer.com/pfizercom/2021-07/Delta_Variant_Study_Press_Statement_Final_7.8.21.pdf?IPpR1xZjlwvaUMQ9sRn2FkePcBiRPGqw
Pfizer and BioNTech

Jul 8th, 2021 - NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial...

Pfizer, BioNTech vaccine neutralises Omicron with three shots undefined
https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-pfizer-say-test-shows-3-doses-vaccine-neutralise-omicron-2021-12-08/

Dec 8 (Reuters) - BioNTech and Pfizer (PFE.N) said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test, an early signal that booster shots could be key to protection against infection from the newly identified variant. The German and U.S. companies said two doses of their vaccine result...

Coronavirus (COVID-19) Update: December 8, 2020 | FDA
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-december-8-2020

Dec 8th, 2020 - For Immediate Release: December 08, 2020 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: Today, the FDA posted online background material for this week’s upcoming Vaccines and Related Biological Products Advisory Committee (VRBPAC) public meeting. The VRBPAC will meet in open session on Thursday, Dec. 10,...

EU Regulator Hopes to Approve COVID Variant-Adapted Vaccines by Autumn
https://www.medscape.com/viewarticle/973476

May 6th, 2022 - (Reuters) - The European Union's drug regulator said on Thursday it hoped to have vaccines adapted to address coronavirus variants, such as Omicron, approved by September. "Our priority is to ensure that adaptive vaccines are possibly approved by September at the latest to be ready for the rollout of new immunisation campaigns in the EU in the autumn," said Marco Cavaleri, head of biolog...

Pfizer Says Updated Vaccines Boost Protection Against Omicron
https://www.medscape.com/viewarticle/976276

Jun 27th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Pfizer and BioNTech announced Saturday that their two Omicron-targeted vaccines are safe and effective against the coronavirus, including the latest Omicron subvariants, according to The Associated Press. The announcement comes days before the FDA is slated to ...

CureVac sues BioNTech over mRNA technology.
https://doi.org/10.1038/s41587-022-01442-8
Nature Biotechnology;

Aug 10th, 2022 - CureVac sues BioNTech over mRNA technology.|2022||

Comirnaty and Pfizer-BioNTech COVID-19 Vaccine
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine
US Food and Drug Administration (FDA)

Jun 17th, 2022 - On August 23, 2021, FDA announced the first approval of a COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and the approved vaccine is marketed as Comirnaty, for the prevention of COVID-19 in individuals 12 years of age and older.

Coronavirus (COVID-19) Update: December 8, 2020
http://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-december-8-2020

For Immediate Release: December 08, 2020 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: Today, the FDA posted online background material for this week’s upcoming Vaccines and Related Biological Products Advisory Committee (VRBPAC) public meeting. The VRBPAC will meet in open session on Thursday, Dec. 10,...

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389395
MMWR. Morbidity and Mortality Weekly Report; Tenforde MW, Self WH et. al.

Aug 27th, 2021 - Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations...

BioNTech Says It Won't Challenge Vaccine Copying in Africa
https://www.medscape.com/viewarticle/968603

Feb 17th, 2022 - (Reuters) - BioNTech's co-founder and top executive said the vaccine maker has no plans to enforce its intellectual property rights should organisations in Africa strike out on their own to produce unauthorised versions of the company's shot. "Our goal is not to keep others from using our technology. Our goal is rather to actively see to it that our technology is available on all contine...

Omicron-Adapted Vaccine Delivery Expected in October, BioNTech Says
https://www.medscape.com/viewarticle/978847

Aug 8th, 2022 - BioNTech expects to begin deliveries of two Omicron-adapted vaccines as soon as October. The German biotech firm, which makes the Pfizer COVID-19 vaccine, announced the update Monday as it reaffirmed its vaccine revenue forecast for the year, according to The Associated Press. BioNTech is expanding its COVID-19 product pipeline to aim for "prolonged and broad protection," Ugur Sah...

Moderna Sees Higher COVID Vaccine Sales Later This Year
https://www.medscape.com/viewarticle/973392

May 5th, 2022 - (Reuters) - Moderna Inc on Wednesday forecast higher vaccine sales for the second half of the year than in the first six months, as it expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall. The U.S. vaccine maker is developing a potential next generation booster targeted at both the Omicron variant and the origin...